Drugs / Irinotecan liposomes
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06577376 | Aug 2024 → Aug 2026 overdue | gastroesophageal adenocarcinoma | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06648525 | Oct 2024 → Apr 2027 expected | intrahepatic cholangiocarcinoma | Harbin Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Irinotecan liposomes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06577376 ↗ |
| Route | Intravenous | “Irinotecan liposomes, IV” NCT06648525 ↗ |